Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
Drug Class Overviews revamped to address the changing needs of health care professionals
Tampa, FL, August 22, 2012 – Leading drug information provider Elsevier / Gold Standard announced today its new Drug Class Overviews, making Clinical Pharmacology more valuable at the point of care.
Clinical Pharmacology Drug Class Overviews are now even more powerful for evaluating formulary decisions and therapeutic drug substitutions. Elsevier / Gold Standard has improved the speed and usability of the content through bulleted summaries and tables, highlighting a variety of critical areas in drug-interaction information.
“The new Drug Class Overviews represent a significant evolution in our content development that was stimulated and driven by input from our clients,” said Elsevier / Gold Standard President Marianne Messer. “This advancement also represents the way in which our users wish to utilize our vast amount of drug information that is updated in real-time.”
The new Drug Class Overviews includes:
- A summary in simple bullet format
- Pharmacology/Mechanism of Action with key pharmacology and pharmacokinetics and tables to highlight differences
- Therapeutic Use, highlighting place in therapy, alternatives within a class, and key clinical differences with labeled, off-label, and not recommended indications
- Comparative Efficacy, highlighting randomized control trials for one or more indications
- Adverse Reactions/Toxicities summarizes serious adverse events and toxicities
- Drug Interactions, helping clinicians determine which drugs to use
- Safety Issues, highlights all contraindications and indicates BBW’s, REMS, or MedGuides.
“Clinical Pharmacology has been named by independent research studies as the most complete and dependable drug reference solution on the market today. It is trusted by thousands of hospitals, 35,000 retail pharmacies, health plans, pharmacy benefit managers (PBMs), pharmaceutical manufacturers, and academic institutions,” Messer said. “We are pleased to continue developing our solutions and meeting the needs of our users.”
For more information about Clinical Pharmacology and the new Drug Class Overviews, please visit www.goldstandard.com.
# # #
About Elsevier / Gold Standard
Based in Tampa, FL, Elsevier / Gold Standard uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Elsevier / Gold Standard solutions empower healthcare organizations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes. To learn more about Elsevier / Gold Standard, visit www.goldstandard.com.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.Media contact
Director, Corporate Relations, Elsevier
+1 212 633 3164